Growth Metrics

Scholar Rock Holding (SRRK) Non-Current Debt (2017 - 2026)

Scholar Rock Holding's quarterly Non-Current Debt came in at $196.6 million in Q1 2026, up 295.28% year-on-year from $49.7 million in Q1 2025, and up 97.19% quarter-over-quarter from $99.7 million in Q4 2025.

Scholar Rock Holding has reported Non-Current Debt for 10 years, with the latest figure at $196.6 million in Q1 2026.

  • For the quarter ending Q1 2026, Non-Current Debt rose 295.28% year-over-year to $196.6 million; the trailing twelve-month figure through Mar 2026 stood at $196.6 million (up 295.28% YoY), and the FY2025 full-year result was $99.7 million, up 98.84% from the prior year.
  • Non-Current Debt for Q1 2026 stood at $196.6 million, up from $99.7 million in the prior quarter.
  • The five-year high for Non-Current Debt was $196.6 million in Q1 2026, with the low at $38.8 million in Q2 2022.
  • Average Non-Current Debt over 5 years is $62.9 million, with a median of $49.8 million recorded in 2022.
  • Year-over-year, Non-Current Debt declined 10.51% in 2024 and soared 295.28% in 2026.
  • Tracing SRRK's Non-Current Debt over 5 years: stood at $49.7 million in 2022, then dropped by 2.13% to $48.7 million in 2023, then advanced by 3.0% to $50.1 million in 2024, then surged by 98.84% to $99.7 million in 2025, then jumped by 97.19% to $196.6 million in 2026.
  • The last three Non-Current Debt figures came in at $196.6 million (Q1 2026), $99.7 million (Q4 2025), and $99.6 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 319.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 105.94 Mn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 1.99 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Scholar Rock Holding 500.61 Mn 20.67 Mn - 196.61 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 196.61 Mn
Mar 31, 2026 196.61 Mn
Dec 31, 2025 99.71 Mn
Dec 31, 2025 99.71 Mn
Sep 30, 2025 99.61 Mn
Sep 30, 2025 99.61 Mn
Jun 30, 2025 49.76 Mn
Jun 30, 2025 49.76 Mn
Mar 31, 2025 49.74 Mn
Mar 31, 2025 49.74 Mn
Dec 31, 2024 50.15 Mn
Dec 31, 2024 50.15 Mn
Sep 30, 2024 50.10 Mn
Sep 30, 2024 50.10 Mn
Jun 30, 2024 48.49 Mn
Jun 30, 2024 48.49 Mn
Mar 31, 2024 44.59 Mn
Mar 31, 2024 44.59 Mn
Dec 31, 2023 48.68 Mn
Dec 31, 2023 48.68 Mn
Sep 30, 2023 49.96 Mn
Sep 30, 2023 49.96 Mn
Jun 30, 2023 49.90 Mn
Jun 30, 2023 49.90 Mn
Mar 31, 2023 49.83 Mn
Mar 31, 2023 49.83 Mn
Dec 31, 2022 49.74 Mn
Dec 31, 2022 49.74 Mn
Sep 30, 2022 49.77 Mn
Sep 30, 2022 49.77 Mn
Jun 30, 2022 38.81 Mn
Jun 30, 2022 38.81 Mn
Mar 31, 2022 43.62 Mn
Mar 31, 2022 43.62 Mn
Dec 31, 2021 48.42 Mn
Dec 31, 2021 48.42 Mn
Sep 30, 2021 24.93 Mn
Sep 30, 2021 24.93 Mn
Jun 30, 2021 24.85 Mn
Jun 30, 2021 24.85 Mn
Mar 31, 2021 24.76 Mn
Mar 31, 2021 24.76 Mn
Dec 31, 2020 24.68 Mn
Dec 31, 2020 24.68 Mn
Sep 30, 2020 6,000.00
Sep 30, 2020 6,000.00
Jun 30, 2020 9,000.00
Jun 30, 2020 9,000.00
Mar 31, 2020 14,000.00
Mar 31, 2020 14,000.00
Dec 31, 2019 9,000.00
Dec 31, 2019 9,000.00
Sep 30, 2019 13,000.00
Sep 30, 2019 13,000.00
Jun 30, 2019 17,000.00
Jun 30, 2019 17,000.00
Mar 31, 2019 20,000.00
Mar 31, 2019 20,000.00
Dec 31, 2018 24,000.00
Dec 31, 2018 24,000.00
Dec 31, 2017 398,000.00
Dec 31, 2017 398,000.00